Lack of association of the NPAS2 gene Ala394Thr polymorphism (rs2305160:G>A) with risk of chronic lymphocytic leukemia

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7169-7174

  Rana, Sobia ^a,b   Shahid, Adeela ^a,c   Ullah, Hafeez ^a   Mahmood, Saqib ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

^c Shalamar Medical and Dental College   (Pakistan)

Author keywords

Cancer; CLL; Genotypes; NPAS2; Polymorphism; rs2305160

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; MELATONIN; NERVE PROTEIN; NPAS2 PROTEIN, HUMAN;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CIRCADIAN RHYTHM SLEEP DISORDER; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PAKISTAN; POLYMERASE CHAIN REACTION; WORK SCHEDULE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MELATONIN; MIDDLE AGED; NERVE TISSUE PROTEINS; PAKISTAN; POLYMERASE CHAIN REACTION; SLEEP DISORDERS, CIRCADIAN RHYTHM; WORK SCHEDULE TOLERANCE;

EID: 84907270633     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7169     Document Type: Article

References (29)

1. Asher G, Schibler U (2006). A CLOCK-less clock. Trends Cell Biol, 16, 547-49.
2. Bartsch C, Bartsch H, Schmidt A, et al (1992). Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta, 209, 153-67.
3. Bertolucci C, Cavallari N, Colognesi I, et al (2008). Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators. Mol Cell Biol, 28, 3070-75.
4. Chen-Goodspeed M, Lee CC (2007). Tumor suppression and circadian function. J Biol Rhythms, 22, 291-98.
5. Chu LW, Zhu Y, Yu K, et al (2008). Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis, 11, 342-48.
6. Costa G, Haus E, Stevens R (2010). Shift work and cancer-considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health, 36, 163-79.
7. DeBruyne JP, Weaver DR, Reppert SM (2007). CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci, 10, 543-45.
8. Döhner H, Stilgenbauer K, Dohner M (1999). Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med, 77, 266-81.
9. Fujino Y (2007). Occupational factors and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pac J Cancer Prev, 8, 97-104.
10. Fu L, Lee CC (2003). The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer, 3, 350-61.
11. Fu L, Pelicano H, Liu J, Huang P, Lee C (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell, 111, 41-50.
12. Hoffman AE, Zheng T, Ba Y, Zhu Y (2008). The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res, 6, 1461-68.
13. Howlader N, Noone AM, Krapcho M, et al (2012). SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http:// seer.cancer.gov.
14. Kermani IA, Dehdilani M, Dolatkhah R (2007). Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin. Asian Pac J Cancer Prev, 8, 367-71.
15. Kucuktulu E (2012). Protective effect of melatonin against radiation induced nephrotoxicity in rats. Asian Pac J Cancer Prev, 13, 4101-05.
16. Luo Y, Wang F, Chen LA, et al (2012). Deregulated expression of cry1 and cry2 in human gliomas. Asian Pac J Cancer Prev, 13, 5725-28.
17. Mirick DK, Davis S (2008). Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev, 17, 3306-13.
18. Mozaheb Z, Hasanzadeh Nazar Abadi MH, Aghaee MA (2012). Chronic lymphocytic leukemia and prognostic factors. Asian Pac J Cancer Prev, 13, 3009-13.
19. Oscier D, Fegan C, Hillmen P, et al (2004). British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol, 125, 294-317.
20. Schernhammer ES, Hankinson SE (2009). Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev, 18, 74-9.
21. Sgambati MT, Linet MS, Devesa SS (2001). Chronic Lymphocytic Leukemia: Epidemiological, Familial, and Genetic Aspests. In 'Chronic Lymphoid Leukemias', Eds Cheson BD, Marcel Dekker, New York pp 33-62.
22. Straif K, Baan R, Grosse Y (2007). Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol, 8, 1065-66.
23. Wang F, Hu Z, Yang R, et al (2011). A variant affecting miRNAs binding in the circadian gene neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. Breast Cancer Res Treat, 127, 769-75.
24. Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y (2009). Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett, 284, 149-56.
25. Yi C, Mu L, de la Longrais IA, et al (2010). The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat, 120, 663-69.
26. Yuan P, Wang S, Zhou F, et al (2014). Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients. Cancer Sci, 105, 825-32.
27. Zhou YD, Barnard M, Tian H, et al (1997). Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci USA, 94,713-18.
28. Zhu Y, Leaderer D, Guss C, et al (2007). Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer, 120, 432-35.
29. Zhu Y, Stevens RG, Leaderer D, et al (2008). Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat, 107, 421-5.